Update On Sequent Scientific Ltd By Monarch Networth Capital
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Key MeetingTakeaways Sequent 2.0:
* Shift in gear for the company as it embarks journey towards Sequent 2.0 wherein focus areas for the company would be value added products and further penetration in geographies such as US, Europe and in Asia with increased focus on customer demand.
* Focus on sterile injectable for growth in phase 2.0.
* Emphasis on farm animals over companion animals.
* No plans of getting into vaccines.
* Within the API segment: no plans of getting into fermentation business and will stick to chemistry based.
CDMO:
* High demand from genes in the API business.
* The company supplies to major animal health companies and it witnessing increased demand from these players.
* Sequent’s delivery would be service oriented and not capability oriented.
* Waiting for FDA approval for the Vizag facility.
Carlyle ownership:
* Benefits includes accessibility of human and financial capital.
* In process of finalising investment plans as many opportunities are abundant in animal health pharma segment.
Stonehaven consultancy:
* Aim is to leverage domain knowledge in the animal health industry with 2 fold focus: Validate Sequent’s sterile business and analyse growth opportunities in the same sterile market.
* Sequent is open to inorganic growth through acquisitions.
To Read Complete Report & Disclaimer Click Here
Please refer disclaimer at https://www.mnclgroup.com/disclaimer
SEBI Registration Number : INZ000043833
Above views are of the author and not of the website kindly read disclaimer
